Ovarian cancer: Rationale and strategies beyond first-line treatment

Chemotherapy for Gynecological Neoplasms: Current Therapy and Novel Approaches

Volumn , Issue , 2004, Pages 471-482

  Muggia, Franco M ^a   Hazarika, Maitreyee ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858229782     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. du Bois A, Luck HJ, Bauknecht T, Meier W, Richter B, Kuhn W, Quaas J, Pfisterer J. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a Phase I/II study of the Arbeitsgeneinschaft Gynakologische Onkologic Ovarian Cancer Study Group. J Clin Oncol 1999;17:46–51.
2. Vasey P, on behalf of the Scottish Gynaecologic Cancer Trials Group. Preliminary results of the SCOTROC trial: a Phase III comparison of paclitaxel–carboplatin (PC) and docetaxel–carboplatin (DC) as first line chemotherapy for stage Ic–IV epithelial ovarian cancer (EOC) [meeting abstr. 804]. Proc Annu Meet Am Soc Clin Oncol 2001;20:202a.
3. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Ovitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000;35:75–93.
4. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992;10(4):513–514.
5. van der Burg ME, van Lent M, Boyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332(10):629–634.
6. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986; 57(9):1725–1730.
7. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, vriesendorp R, Kuoyman CD, van Lindert AC, Hamerlynck JV, van Lent M, van Houwelingen JC. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2(8403):594–600.
8. du Bois A, Luck HJ, Buser K, Meerpohl HG, Sessa C, Klassen U, Meden H, Bochtler H, Diegarten K. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. Eur J Cancer 1997;33(3):379–384.
9. Muggia FM, Braly PS, Brady WF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18(1):106–115.
10. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabeli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15(6):2183–2193.
11. Neijt JP, du Bois A. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer. Semin Oncol 1999;26:78–83.
12. Ozols RF. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 1999;26:84–89.
13. Sandercock J, Parmar MKB, Torri V, Qian W. First-line chemotherapy for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002;87:815–824.
14. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312–3322.
15. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15(3):987–993.
16. Misset J-L, Vennin P, Chollet P, et al. Multicenter phase II–III study of oxaliplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol 2001;12:1411–1415.
17. Garcia A, Muggia FM. Activity of anthracyclines in refractory ovarian cancer: recent experience and review. Cancer Invest 1997;15:329–334.
18. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a GOG study. J Clin Oncol 1998;16:405–410.
19. Burger RA, DiSaia PJ, Roberts JA, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999;72:148–153.
20. Thigpen JT, Blessing J, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian cancer after platinum-based chemotherapy: a GOG study. J Clin Oncol 1994; 12:1748–1753.
21. Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837–842.
22. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1343– 1345.
23. Wasserman T, Carter SK. Tabular analysis of anticancer drug activity. Cancer Chemother 1975;6(3):399–419.
24. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16:3345–3352.
25. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8(10):963–968.
26. Diederik FS, Kehrer DF, Bos AM, Verweij J, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 2002;20(5):1222–1231.
27. Verschraegen CF, Gupta E, Loyer E, et al. A Phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory ovarian, tubal or peritoneal cancer. Anticancer Drugs 1999;10(4):375–383.
28. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992;10:243–248.
29. Markman M, Blessing JA, Moore D, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian carcinoma: a GOG phase II trial. Gynecol Oncol 1998;69:226–229.
30. Welander CE. Interferon in the treatment of ovarian cancer. Semin Oncol 1988;15:26–29.
31. Muggia FM, Liu PY, Alberts DS, Wallace DL, O’Toole RV, Terada KY, Franklin EW, Herrer GW, Goldberg DA, Hannigan EV. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy—a randomized Phase II study by the Southwest Oncology Group. Gynecol Oncol 1996;61:395–402.
32. Muggia FM, Jeffers S, Muderspach L, et al. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Gynecol Oncol 1997;66:185–191.
33. Liu J, Liebes L, Fry D, Buckley M, Jacobs A, Liu P, et al. Phase I and pharmacologic study of intraperitoneal topotecan and cisplatin [abstr. 5333]. Proc Am Assoc Cancer Res, 2003.
34. Barakat RC, Sprigss DR. Memorial Sloan-Kettering Cancer Center experience with intraperitoneal chemotherapy of ovarian cancer. In: Markman M, ed. Current Clinical Oncology: Regional Chemotherapy. Totowa, NJ, USA: Humana Press, Inc., 2000:167–177.
35. Epenetos AA, Hird V, Lambert H, et al. Long-term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Oncol 2000;10(51):44–46.
36. Rothenberg M, Liu PY, Wilczynski S, et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 2001;82:317–322.
37. Shirey DR, Kavanagh JJ Jr, Gershenson DM, Freedman RS, Copeland LJ, Jones LA. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985;66(4):575–578.
38. Trope C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000;36(suppl 4):S59–S61.
39. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996;62(1):1–3.
40. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82(4):812–817.
41. Ehlen T, Nicodemus CF, Noujaim AA, et al. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Oncol 2000;10(S1):44–66.
42. Muggia FM. Search for the optimal treatment of ovarian cancer: heavy metals, “belly baths” and …yew trees. J Clin Oncol 1992;10:683–685.
43. Muggia FM. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 1989;16(suppl 5):1–7.
44. Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized Phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000;18:1193–2002.
45. Verschraeggen C, Mansfield P, Feig B, et al. Phase I study of an intraperitoneal liposomal cisplatin analog L-NDDP for treatment of peritoneal carcinomatosis [abstr. 1405]. Proc Am Soc Clin Oncol 1999;18:364a.
46. Gietema JA, De Vries EGE, Sleijfer DT, et al. A Phase I study of 1,2-diammineomethyl-cyclobutane-platinum (II)-lactate-(D-19466, lobaplatin) administered daily for 5 days. Br J Cancer 1993;67:396–401.
47. Gietema JA, Velduis GJ, Guchelaar HJ, et al. Phase II and pharmacokinetic study of lobaplatin with relapsed ovarian cancer. Br J Cancer 1995;71:1302–1305.
48. Akaza H, Togashi M, Nishio Y, et al. Phase II study of cisdiammine(glycolato) platinum, 265-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and tran-sitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 1992;31:187– 192.
49. McKeage MJ, Raynaud E, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15: 2691–2700.
50. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002;201:1232– 1237.
51. Bolis G, Scarfgone G, Giardina G, et al. Carboplatin alone vs carboplatin plus epido-xorubicin as second-line therapy for cisplatin-or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001;81:3–9.
52. Viens P, Bougnoux P, Dieras V, et al. A phase II trial of oxaliplatin and paclitaxel combination in advanced ovarian cancer patients pretreated with cisplatin or carboplatin+ taxanes: preliminary results [abstr. 889]. Proc Am Soc Clin Oncol 2002;21:223a.
53. Muggia FM. Hexamethylmelamine in platinum-resistant ovarian cancer: how active? Gynecol Oncol 1992;47:279–281. Editorial.
54. Kavanagh JJ, Kudelka AP, Garcia A, Lewis L, Bolanos-Clark M, Maack C, Jameson A, Henner WD, Brown GL. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory or resistant 5 third-line advanced ovarian cancer [abstr. 1816]. Proc Am Soc Clin Oncol 2003;22.
55. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the progress in early stage (FIGO I–II) epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11, 119–129.
56. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267– 3279.
57. Small JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL, Denny WA. Tyrosine kinase inhibitors: 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J Med Chem, 2001, 429– 440.
58. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human–mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999;18:731–738.
59. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden andprolongs survival of mice bearinghuman ovarian carcinoma xenografts. Cancer Res 1993;53:2087–2091.
60. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4:1101–1109.
61. Nammi S, Lodagala DS. Ras farnesyltransferase inhibition: a novel and safe approach to cancer chemotherapy. Acta Pharmacol Sinica 2000;21:396–404.
62. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putman JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985–991.
63. Haigentz M Jr, Kim M, Sorich J, Lee J, Hochster H, Macapinlac M, Mirchandani D, Sewak S, Pavlick A, Volm M, Hamilton A, Muggia FM. Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. Anticancer Drugs 2003;14(4):321–326.
64. 2. Ann Oncol 2000;11:1029– 1033.
65. Karthaus M, Ballo H, Steinmetz T, Geer T, Schimke J, Braumann D, Behrens R, Kindler M, Greinwald R, Kleeberg U. Budesonide for prevention of irinotecan (CPT-11)-induced diarrhea. Results of a double-blind, placebo-controlled, multicenter, randomized phase-III-study in patients with advanced colorectal cancer (CRC) [abstr. 2935]. Proc Am Soc Clin Oncol 2003;22.
66. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer. The ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099–2106.